NCT04158258 2026-02-12
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
Clinical Trials
12 trialsNCT06961331 2026-01-09
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Pfizer
Completed
NCT06035016 2023-09-13
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
Peking Union Medical College Hospital
Recruiting
NCT05131893 2021-11-23
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Not yet recruiting
NCT04258163 2020-02-10
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed
NCT02479217 2017-02-17
Safety of Xeloda in Solid Tumours
Hoffmann-La Roche
Completed
NCT02656589 2016-10-13
microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT01725386 2016-09-28
XEPAD
Hoffmann-La Roche
Completed
NCT01777945 2016-08-19
XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer
Hoffmann-La Roche
Completed
NCT01664494 2016-05-02
An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
Hoffmann-La Roche
Completed
NCT00235235 2015-12-09
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Hoosier Cancer Research Network
Terminated
NCT01782651 2015-08-10
Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
GlaxoSmithKline
Completed